Kornimate/medical-research-clean huggingface dataset:
rehabilitation program for the sequelae of covid 19 infection

Conditions: Covid19

Summary: subproject 1: describe the situation of post-covid patients in terms of muscle (skeletal and respiratory), cognitive, emotional and health-related quality of life in the 1st visit of the multidisciplinary post-covid rehabilitation consultation at the hospital. retrospective observational study. the data collected in clinical records during the first visit in the post-covid rehabilitation consultation will be analysed. subproject 2: evaluate the response to a personalized rehabilitation program in patients with post-covid sequelae in terms of muscle (skeletal and respiratory), and health-related quality of life. prospective observational study of a single cohort of patients. the data will be collected from successive clinical visits.


Eligibility criteria:
inclusion criteria: * • patients who were diagnosed with covid-19 pneumonia, confirmed by serological tests or molecular biology test (pcr), and who were at home at the time of the 1st visit. * pcr or serological negative test or more than 28 days after diagnosis. * dyspnoea in activities of daily living (mmrc ≥ 2), (annex 5 of the clinical protocol). * patients who had muscle weakness (clinical frailty scale ≥ 3), (annex 1 of the clinical protocol). exclusion criteria: * patients with disease activity. * live outside the reference area of the hospital de la santa creu i sant pau. * patients with cognitive impairment that makes it difficult to carry out the rehabilitation program.
capabilities of perinatal healthcare institutions in the federation of bosnia and herzegovina

Conditions: Prenatal Care

Summary: the aim of this study is to assess the level of the perinatal healthcare institution (phi) where the newborns were delivered. we included newborns of both genders that were born in the maternity wards in 10 cantons of the federation of bosnia and herzegovina (fbih). from the phi of the first and second level, 159 newborns were referred to the third level. out of a total of 159 lbwi referred from other phi, only 19.5% lbwi were transported in less than 4 hours. in second level phi, most lbwi died in the first 12 hours after birth.


Eligibility criteria:
inclusion criteria: * newborns of both genders that were born in the maternity wards in 10 cantons of the fbih * a gestational age between 22 and 42 weeks, and a birth weight less than 2500g. exclusion criteria: * infants younger than 22 weeks or older than 42 weeks. * infants whose mothers refused to give consent for participation in the study.
psychological effects of implant loss

Conditions: Breast Cancer Female

Summary: previous quality of life studies have suggested that long term satisfaction with breast reconstruction may be affected by postoperative complications. complication frequencies, especially the risk for implant loss, is considerably higher in immediate than in delayed breast reconstruction. knowledge about how implant loss affects the patient's experience of her breast reconstruction can guide us in the choice between immediate and delayed breast reconstruction in high risk patients and help us better prepare the patients for possible complications. this study will investigate patients' experiences with losing an implant in connection with immediate breast reconstruction.


Eligibility criteria:
inclusion criteria: * biological women * age \>18 years * have lost an implant after a mastectomy and immediate breast reconstruction exclusion criteria: * inability to give informed consent * inability to speak and understand swedish * relapse of breast cancer after the reconstruction * metastatic disease * psychiatric co-morbidity.

Keywords: breast reconstruction plastic surgery psychology
perioperative pain management for lumbar spine surgery

Conditions: Pain, Postoperative

Summary: perioperative pain management is crucial for patients undergoing elective lumbar spine surgery. moderate to severe postoperative pain can significantly impact recovery, worsen patient outcomes, and potentially lead to chronic pain. opioids have traditionally been the mainstay of postoperative pain management. however, their use is associated with several adverse effects, including nausea, vomiting, respiratory depression, and the risk of developing chronic pain. to mitigate these risks, there is a growing emphasis on multimodal analgesic approaches that combine various non-opioid medications to provide effective pain relief. non-opioid analgesics, such as nonsteroidal anti-inflammatory drugs (nsaids), regional anesthesia techniques, and adjuvant medications, can be used to reduce opioid requirements and improve patient outcomes. by carefully selecting and combining these modalities, clinicians can optimize pain management strategies for individual patients, minimizing the need for opioids and their associated side effects.


Eligibility criteria:
inclusion criteria: * patients who had ldd and required lumbar discectomy, * patients are free of exclusion criteria and accepted to participate in the study. exclusion criteria: * the presence of other indications for spinal surgery; * obesity of grade ≥ii; * patients of asa grade \>ii; * opioid dependence for preoperative pain; * the presence of other causes of preoperative pain; * the presence of preoperative psychiatric manifestations especially delirium and/or cognitive dysfunction; * the presence of contraindications for the use of the study drugs; * the presence of uncontrolled cardiac, renal, or hepatic disorders and essential hypertension.
return to golf after orthopaedic surgery

Conditions: Hip Osteoarthritis; Knee Osteoarthritis; Shoulder Osteoarthritis

Summary: the golf study is a multicenter, prospective study with the goal to investigate golfers' return to the sport following hip, knee or shoulder arthroplasty. the prevalence of return to golf, by level of returning to golf will be assessed at 6 weeks, 3 months, 6 months, and 12 months postoperatively. patients who are active golfers undergoing joint replacement will be identified from outpatient clinics and pre-assessment clinics and given information about the study at least two weeks prior to surgery. participants in this study must have a desire to return to golf after surgery. previous studies have only been able to report the return to golf after arthroplasty retrospectively; the prospective nature of this study will allow for a greater understanding of this process.


Eligibility criteria:
inclusion criteria: * age 18+ years * a self-reported golfer * able to consent to treatment * indicated for one of the following surgical procedures: total hip arthroplasty, hip resurfacing, revision hip arthroplasty, total knee arthroplasty, unicompartmental knee arthroplasty, revision knee arthroplasty, total shoulder arthroplasty, reverse shoulder arthroplasty, shoulder resurfacing arthroplasty, revision shoulder arthroplasty exclusion criteria: * inability to complete follow-up questionnaires * declining operative management * no desire to return to golf postoperatively * medical problem that affects the patient's ability to play golf (e.g., angina, shortness of breath, etc.)

Keywords: return to golf, arthroplasty
pet/ct imaging of aneurysm wall inflammation

Conditions: Aortic Aneurysm

Summary: rationale: aneurysm development, progression and rupture are characterised by extensive inflammation, dominated by the infiltration of t-cells, b-cells and macrophages. recent studies into the pathophysiology of aneurysm wall degradation suggest a close relation between increased mechanical stress and the local activation of infiltrated lymphocytes and macrophages. the non-invasive detection of aneurysm wall inflammation, using 18-fluorodeoxyglucose positron emission tomography (fdg-pet) might therefore provide valuable information on the extend of the disease and could clarify the role of mechanical stress on the propagation of aneurysm wall inflammation. objective: correlation of fdg uptake and in vitro aneurysm wall tensile strength. (primary objective). the effect of aneurysm sac depressurisation, after endovascular aneurysm repair, on aneurysm wall inflammation (secondary objective). study design: observational case series (pilot). study population: patients scheduled for conventional (open) and endovascular aneurysm repair. main study parameters: standard uptake value (suv) measurements to asses fdg uptake in the aneurysm wall and in vitro aneurysm wall strength (n/mm). nature and extent of the burden and risks associated with participation, benefit and group relatedness: patients scheduled for conventional (open) or endovascular aneurysm repair are admitted to the hospital the day before surgery. at that point all patients will be evaluated using fdg-pet. although intake of sugar-free liquids is permitted, glucose intake is restricted 6 hours prior to fdg-pet imaging. one hour after intravenous injection of 200-220 mbq fdg, whole body emission and transmission images will be acquired. to determine inflammation markers ( e.g. crp), blood and urine samples will be collected prior to the operation and again 6 weeks after surgery. for in vitro aneurysm wall tensile strength testing wall specimens will be harvested during conventional aneurysm repair.


Eligibility criteria:
inclusion criteria: * scheduled for conventional (10 patients) or endovascular (25 patients) aneurysm repair. * informed consent exclusion criteria: * diabetes mellitus type 1 en 2
calcified lesion intervention planning steered by oct.

Conditions: Coronary Artery Calcification; Angioplasty

Summary: calcified lesions are very frequent among coronary artery disease stenotic lesions. the prevalence of calcifications ranges from 30 to 40% (by angiography evaluation) but is higher when analyzed by intra coronary imaging. calcified lesions are very frequent among coronary artery disease stenotic lesions. the prevalence of calcifications ranges from 30 to 40% (by angiography evaluation) but is higher when analyzed by intra coronary imaging. the presence of calcifications increases the risk of adverse evolution after pci , including stent restenosis, thrombosis and need for repeat revascularisation. specific and appropriate tools can be used for calcified lesions management , including high pressure non compliant balloons, intravascular lithotripsy and rotablator. intra vascular oct has a high sensitivity and specificity for calcium detection among coronary artery lesions. compared to ivus, oct allows a better quantification of calcium sheets (depth extension ) . several intra coronary imaging based calcified lesions management algorithms have been proposed , but none have been validated in clinical practice.


Eligibility criteria:
inclusion criteria: 1. patient with chronic coronary syndrome 2. angiographically moderately to severely calcified target lesion, defined as follows: * moderate: lesion with radio-opacities noted only during the cardiac cycle before contrast dye injection (aksoy et al., circ cardiovasc interv 2019) * severe: lesion with radio-opacities seen without cardiac motion before contrast dye injection, visible on both sides of the arterial lumen(aksoy et al., circ cardiovasc interv 2019) 3. possibility to cross the target lesion with oct catheter exclusion criteria: 1. on-going cardiogenic shock 2. acute coronary syndrome related to target lesion 3. severe renal failure (creatinine clearance: 30 ml/min/m2) 4. impossibility to cross target lesion with oct catheter \& balloons, 5. indication for rotablator device as first line therapy 6. pregnancy 7. age \< 18 y 8. denial to provide consent

Keywords: optical coherence tomography, oct minimal stent area(msa)
occupational therapy rehabilitation for frail elders with dysphagia

Conditions: Dysphagia, Oropharyngeal; Deglutition Disorders

Summary: the goal of this proof-of-concept study is to assess the potential of a newly developed intervention with combined skill- and strength-based principles for maximizing swallowing-related outcomes and prevent further weakening of the swallowing muscles in older people with dysphagia (difficulty swallowing). the main questions to be answered are: 1. does the intervention produce clinically significant improvement in ingestive skills during meals in older individuals with dysphagia? 2. does the intervention produce clinically significant improvements in tongue strength and orofacial function in older persons with dysphagia? 3. does the intervention produce clinically significant improvements in nutritional status and quality of life in older individuals with dysphagia? 4. is there an association between perceived autonomy support and intervention engagement when older individuals with dysphagia receive the intervention during hospitalization and continued in community-based rehabilitation after discharge? participants will be asked to perform goal-directed and task-specific swallowing exercises in eating and drinking activities where the intensity variables include advancing steps of an altered bolus volume and consistency according to a 17-level task hierarchy, which are introduced according to predetermined progression rules, as well as increases in swallowing repetitions. the dosage is 2-3 individual, face-to-face therapy sessions per week for up to a maximum of eight weeks. a therapy session lasts up to 45 min. in between therapy sessions, participants integrate the achieved level from therapy into their daily meals as self-training.


Eligibility criteria:
inclusion criteria: * a score of 5-18 on the gugging swallowing screen. * speaks and understands danish. * are able to cooperate in the intervention and give written informed consent; i.e. is oriented in time, place and own data, and able to perform four simple oral motor movements on request. * has given written informed consent. exclusion criteria: * esophageal dysphagia. * progressive neurologenic dysphagia. * psychiatric illness. * delirious. * infections that requires isolation. * need for palliative care.
a long-term safety and tolerability study of bapineuzumab in alzheimer disease patients

Conditions: Alzheimer Disease

Summary: the purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with alzheimer disease who participated in study 3133k1-3000 (nct00667810). over 250 sites will participate in over 26 countries. subjects will receive bapineuzumab. each subject's participation will last approximately 4 years.


Eligibility criteria:
inclusion criteria: * subject has completed study 3133k1-3000 and brain magnetic resonance imaging (mri) scan consistent with the diagnosis of alzheimer disease * mini-mental status examination (mmse) \>=10 at screening * caregiver able to attend all clinic visits with subject exclusion criteria: * any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response. * any significant brain mri abnormality. * use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening

Keywords: antibody
a nutritional intervention and physical activity program reduce body weight in women newly diagnosed with breast cancer.

Conditions: Breast Cancer; Body Weight Changes; Weight Loss; Nutrition Related Cancer

Summary: to evaluate a nutritional intervention for women newly diagnosed with breast cancer on a weight control and physical activity program.

56 women newly diagnosed with breast cancer from the department of medical oncology of la paz university hospital, madrid, spain. a nutritional and physical activity intervention program that consisted of two individual nutritional consults and five nutritional group lectures was conducted by physicians of the nutrition unit during one year.

Eligibility criteria:
inclusion criteria: * years: ≥18 * sex: female * newly diagnosed breast cáncer exclusion criteria: * patients who have disseminated disease. * associated eating behavior disorders. * patients with dementia, mental illness or decreased cognitive function. * consumption of drugs or substances to lose weight (except in those cases in which it is suspended 15 days before starting the study). * presence of disease that may interfere with weight loss: severe psychiatric illness, uncontrolled hypothyroidism. * pregnant or breastfeeding women.
exploratory study of farletuzumab to treat resectable, non-functioning pituitary adenomas

Conditions: Resectable, Non-functioning Pituitary Adenoma

Summary: the purpose of this study is to evaluate whether therapy with farletuzumab is effective and safe in the treatment of resectable, non-functioning pituitary adenomas.

non-functioning pituitary adenomas are the most frequent type of pituitary tumors, defined by the lack of hormonal overproduction from the tumor. non-functioning macroadenomas are \> 1 cm in size that can cause progressive visual loss, headaches, and symptoms of pituitary dysfunction (hypopituitarism and/or hyperprolactinemia). initial treatment for these type of tumors is trans sphenoidal surgical resection. in cases where the outcome is incomplete surgical resection of the tumor, repeat surgery and external beam radiation therapy may be performed. previous clinical work suggests there may be a role for a folate receptor in the treatment of non-secretory, pituitary adenomas. morab-003 is a monoclonal antibody that has the potential to be an effective agent against resectable, non-functioning pituitary adenomas. morab-003 has been shown to be well tolerated. this study allows the opportunity to determine if therapy with farletuzumab is effective and safe.

Eligibility criteria:
inclusion criteria: * males and females \>18 years old * diagnosis of non-functional pituitary adenoma * able and willing to undergo surgical resection of the pituitary tumor * significant medical conditions must be well-controlled and stable for at least 30 days prior to signing the informed consent form exclusion criteria: * presence of clinically significant pituitary apoplexy * presence of hormone-secreting adenomas * presence of compressive optic neuropathy due to pituitary tumor * no prior surgical, medical, or radiation therapy in the last 6 months

Keywords: resectable, non-functioning pituitary adenoma pituitary tumor pituitary adenoma pituitary macroadenoma
non-invasive neurostimulation in parkinson's disease

Conditions: Parkinson's Disease

Summary: in this study, the investigators aim to investigate the effects of non-invasive neurostimulation - low-intensity transcranial electrical stimulation in conjunction with transcranial ultrasound (tus)- on the motor symptoms associated with parkinson's disease. the investigators want to see if there is a difference between active and sham stimulation on these motor symptoms.


Eligibility criteria:
inclusion criteria: * documentation of pd diagnosis from their clinician by either a letter or verification through their medical record * research criteria of "possible" or "probable" pd, as defined by gelb et al (gelb d, oliver e, gilman s. diagnostic criteria for parkinson disease. arch neurol.1999;56:33-39)\[1\] * age 40 or over; * taking stable medications for at least 30 days exclusion criteria: * features suggestive of other causes of parkinsonism/parkinson's-plus syndromes; * history of deep brain stimulation or ablation surgery, mass brain lesions; * history of schizophrenia, schizoaffective disorder, other psychosis, episode of bipolar illness, alcohol/drug abuse within the past year; * need for rapid clinical response due to conditions such as initiation, psychosis, or suicidal; * contraindications to transcranial brain stimulation or tus, i.e. metal in the head, implanted brain medical devices, etc; * unstable medical conditions (e.g. uncontrolled diabetes, uncompensated cardiac issues, heart failure, pulmonary issues, or chronic obstructive pulmonary disease); * pregnancy. * epilepsy or disorders that increase likelihood of seizures including: moderate or severe traumatic brain injury, congenital birth defects leading to seizures, brain tumor, metabolism disorders associated with seizures, and nonlacunar stroke.

Keywords: noninvasive stimulation motor function transcranial stimulation transcranial ultrasound brain stimulation
the clinical value of chromoendoscopy as surveillance strategy for dysplasia detection in ulcerative colitis

Conditions: Ulcerative Colitis; Chromoendoscopy

Summary: a recent multicentre randomised controlled trial compared autofluorescence imaging (afi) with ce for dysplasia detection in colonoscopy surveillance of patients with longstanding uc (find-uc). in this study, ce detected significantly more dysplastic lesions per patient compared with afi. it is unclear whether this increased dysplasia detection also translates to a reduction of dysplasia at follow-up colonoscopy. the aim of this pre-specified study is therefore to prospectively determine whether there is a difference in dysplasia detection at follow-up colonoscopy between uc patients who were randomized to afi or ce at index colonoscopy for the find-uc trial.


Eligibility criteria:
patients are eligible for inclusion in this study when they meet the following criteria: inclusion criteria in order to be eligible to participate in this study, a subject must meet all of the following criteria: - patients that where included in the previous find-uc trial exclusion criteria a potential subject who meets any of the following criteria will be excluded from participation in this study: * patients who not receive their surveillance colonoscopy with ce * patients who not undergo their surveillance colonoscopy within 3 months of the surveillance recommendations withdrawal of individual subjects a patient will be excluded from the study if any of the following events occur: * withdrawal of informed consent * the patient requests to be discontinued from the study * the bowel preparation is scored as boston bowel preparation scale \<6 * incomplete colonoscopy because the endoscopist is unable to intubate the cecum during the colonoscopy * the mayo-score \> 1 in at least in one of the bowel segments

Keywords: surveillance chromoendoscopy dysplasia ulcerative colitis
pharmacokinetics, efficacy and safety of abatacept administered subcutaneously (sc) in children and adolescents with active polyarticular juvenile idiopathic arthritis (pjia) and inadequate response (ir) to biologic or non biologic disease modifying anti-rheumatic drugs (dmards)

Conditions: Active Polyarticular Juvenile Idiopathic Arthritis

Summary: the purpose of this study is to estimate abatacept steady-state trough concentration (cmin) at day 113 in children and adolescents with pjia


Eligibility criteria:
inclusion criteria: * jia subjects (male or female), ages 2-17 years with active disease who had an insufficient therapeutic response or intolerance to at least one non biologic dmard or tumor necrosis factor (tnfα) antagonists for at least 3 months prior to screening * subjects with tnfα inadequate response (or prior biologic) will be restricted to 30% of the population * subjects must have a history of at least 5 joints with active disease and must have currently active articular disease with ≥2 active joints and ≥2 joints with limitation of motion. exclusion criteria: * subjects with other rheumatic diseases or major chronic inflammatory/immunologic diseases, active uveitis, systemic jia with active systemic features (within a period of 6 months prior to enrollment), persistent oligoarthritis jia, or failed 3 or more tnfα antagonists or other biological dmards will be excluded. * active systemic disease: (ie, extra-articular features of systemic jia including fever, rash, organomegaly) within a period of 6 months prior to randomization. * subjects who have failed more than two tnfα antagonists or other biologic dmards